Related Experiment Video
Updated: Jul 7, 2026
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
[Bone marrow immunophenotyping for the diagnosis of multiple myeloma: practical aspects]
Insights
Flow cytometric immunophenotyping rapidly identifies malignant plasma cells in multiple myeloma. This method aids in determining cell phenotype and distinguishing between transformed and normal plasma cells for clinical application.
Area of Science:
- Hematology
- Immunology
- Cell Biology
Context:
- Multiple myeloma is a plasma cell malignancy.
- Accurate diagnosis and characterization are crucial.
- Flow cytometry offers rapid cellular analysis.
Purpose:
- To present an immunophenotyping strategy for multiple myeloma.
- To detail an algorithm for verifying transformed plasma cells.
- To highlight practical and clinical aspects of the assay.
Summary:
- Utilizes three-color monoclonal antibodies (CD35, CD14, CD38, CD138, CD19).
- Establishes a method to identify malignant plasma cell clones.
- Differentiates transformed from normal plasma cells.
Impact:
- Facilitates timely diagnosis of multiple myeloma.
- Provides detailed phenotypic information for treatment decisions.
- Enhances the clinical utility of flow cytometry in plasma cell disorders.
Abstract:
Multiple myeloma is a malignant proliferative disease of plasma cells. Flow cytometric immunophenotyping makes it possible to identify a malignant clone of myeloma cells in the shortest possible time, to determine its phenotype, and differentiate transformed and preserved plasma cells. The article presents an immunophenotyping strategy using three-color monoclonal antibodies (CD35, CD14, CD38, CD138, and CD19) and an algorithm of verification of transformed plasma cells. Particular emphasis is placed on both the practical aspects of performing this assay and on the clinical application of the obtained results.
